- Home
- SWZ vs UNCY Comparison
SWZ vs UNCY Comparison
Compare SWZ & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWZ
- UNCY
- Stock Information
- Founded
- SWZ 1986
- UNCY 2016
- Country
- SWZ United States
- UNCY United States
- Employees
- SWZ N/A
- UNCY N/A
- Industry
- SWZ Finance Companies
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- SWZ Finance
- UNCY Health Care
- Exchange
- SWZ Nasdaq
- UNCY Nasdaq
- Market Cap
- SWZ 79.1M
- UNCY 74.2M
- IPO Year
- SWZ N/A
- UNCY 2021
- Fundamental
- Price
- SWZ $6.12
- UNCY $4.20
- Analyst Decision
- SWZ
- UNCY Strong Buy
- Analyst Count
- SWZ 0
- UNCY 4
- Target Price
- SWZ N/A
- UNCY $63.75
- AVG Volume (30 Days)
- SWZ 14.2K
- UNCY 481.2K
- Earning Date
- SWZ 01-01-0001
- UNCY 08-14-2025
- Dividend Yield
- SWZ 6.59%
- UNCY N/A
- EPS Growth
- SWZ N/A
- UNCY N/A
- EPS
- SWZ N/A
- UNCY N/A
- Revenue
- SWZ N/A
- UNCY N/A
- Revenue This Year
- SWZ N/A
- UNCY N/A
- Revenue Next Year
- SWZ N/A
- UNCY $1,178.98
- P/E Ratio
- SWZ N/A
- UNCY N/A
- Revenue Growth
- SWZ N/A
- UNCY N/A
- 52 Week Low
- SWZ $7.12
- UNCY $2.83
- 52 Week High
- SWZ $8.57
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- SWZ 46.11
- UNCY 43.75
- Support Level
- SWZ $6.03
- UNCY $3.86
- Resistance Level
- SWZ $6.20
- UNCY $4.97
- Average True Range (ATR)
- SWZ 0.06
- UNCY 0.31
- MACD
- SWZ 0.00
- UNCY 0.04
- Stochastic Oscillator
- SWZ 44.74
- UNCY 30.63
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.